Olema Pharmaceuticals Inc
NASDAQ:OLMA
Income Statement
Earnings Waterfall
Olema Pharmaceuticals Inc
Income Statement
Olema Pharmaceuticals Inc
| Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||
| Interest Expense |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | ||||||||||||||||||||||
| Operating Expenses |
(12)
|
(22)
|
(36)
|
(50)
|
(60)
|
(71)
|
(79)
|
(96)
|
(102)
|
(107)
|
(113)
|
(102)
|
(102)
|
(105)
|
(110)
|
(122)
|
(136)
|
(142)
|
(143)
|
(157)
|
(165)
|
|
| Selling, General & Administrative |
(4)
|
(8)
|
(12)
|
(16)
|
(18)
|
(20)
|
(23)
|
(25)
|
(25)
|
(25)
|
(24)
|
(22)
|
(20)
|
(19)
|
(17)
|
(17)
|
(18)
|
(18)
|
(18)
|
(17)
|
(19)
|
|
| Research & Development |
(8)
|
(14)
|
(24)
|
(34)
|
(41)
|
(51)
|
(56)
|
(72)
|
(77)
|
(82)
|
(89)
|
(80)
|
(82)
|
(86)
|
(93)
|
(104)
|
(118)
|
(125)
|
(125)
|
(140)
|
(147)
|
|
| Operating Income |
(12)
N/A
|
(22)
-73%
|
(36)
-67%
|
(50)
-39%
|
(60)
-20%
|
(71)
-19%
|
(79)
-11%
|
(96)
-21%
|
(102)
-6%
|
(107)
-5%
|
(113)
-6%
|
(102)
+10%
|
(102)
0%
|
(105)
-3%
|
(110)
-5%
|
(122)
-11%
|
(136)
-12%
|
(142)
-5%
|
(143)
0%
|
(157)
-10%
|
(165)
-5%
|
|
| Pre-Tax Income | ||||||||||||||||||||||
| Interest Income Expense |
(1)
|
(1)
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
2
|
3
|
4
|
6
|
8
|
10
|
12
|
13
|
13
|
14
|
15
|
16
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
(0)
|
|
| Pre-Tax Income |
(13)
N/A
|
(22)
-70%
|
(36)
-62%
|
(50)
-39%
|
(60)
-20%
|
(71)
-19%
|
(79)
-11%
|
(95)
-21%
|
(100)
-5%
|
(105)
-5%
|
(110)
-5%
|
(97)
+12%
|
(96)
+1%
|
(97)
-1%
|
(99)
-3%
|
(110)
-10%
|
(123)
-12%
|
(129)
-6%
|
(129)
+0%
|
(142)
-10%
|
(150)
-5%
|
|
| Net Income | ||||||||||||||||||||||
| Income from Continuing Operations |
(13)
|
(22)
|
(36)
|
(50)
|
(60)
|
(71)
|
(79)
|
(95)
|
(100)
|
(105)
|
(110)
|
(97)
|
(96)
|
(97)
|
(99)
|
(110)
|
(123)
|
(129)
|
(129)
|
(142)
|
(150)
|
|
| Net Income (Common) |
(15)
N/A
|
(24)
-61%
|
(38)
-57%
|
(52)
-37%
|
(60)
-16%
|
(71)
-19%
|
(79)
-11%
|
(95)
-21%
|
(100)
-5%
|
(105)
-5%
|
(110)
-5%
|
(97)
+12%
|
(96)
+1%
|
(97)
-1%
|
(99)
-3%
|
(110)
-10%
|
(123)
-12%
|
(129)
-6%
|
(129)
+0%
|
(142)
-10%
|
(150)
-5%
|
|
| EPS (Diluted) |
-0.38
N/A
|
-0.62
-63%
|
-0.96
-55%
|
-1.32
-38%
|
-1.52
-15%
|
-1.8
-18%
|
-1.99
-11%
|
-2.39
-20%
|
-2.51
-5%
|
-2.62
-4%
|
-2.74
-5%
|
-2.38
+13%
|
-2.13
+11%
|
-2.14
0%
|
-1.78
+17%
|
-1.94
-9%
|
-2.14
-10%
|
-2.2
-3%
|
-1.5
+32%
|
-1.66
-11%
|
-1.74
-5%
|
|